New car financing is available for under 4% APR for borrowers with high credit scores Written By Written by Staff Senior Editor, Buy Side Miranda Marquit is a staff senior personal finance editor for ...

Learn how car loans work and how to find the best one for you Betsy began her career in international finance and it has since grown into a comprehensive approach to journalism as she's been able to ...

Penny Gusner is a senior insurance writer and analyst at Forbes Advisor. For more than 20 years, she has been helping consumers learn how insurance laws, data, trends, and coverages affect them. Penny ...

Next to a house, a car is the most expensive purchase most people will make. If you're financing your vehicle, choosing the right lender can save you thousands in interest and fees. There's a lot to ...

Avonex is a prescription drug that treats relapsing forms of multiple sclerosis (MS) in adults, such as relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome.

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

Skytrofa is administered as a once weekly injection. It comes as a powder in cartridges that you load into an auto-injector device. The dosage of Skytrofa will vary based on your age, weight, and ...

Fresenius Kabi and Phlow are joining together to boost U.S. supply of epinephrine injections through a novel onshoring drive. The collaboration is billed as the “first-ever” end-to-end manufacturing ...

Management attributed the 3% revenue decline in 2025 to the loss of exclusivity for Atozet and headwinds in the respiratory franchise, specifically policy-driven impacts on Singulair. The biosimilars ...

Earnings call Organon reported 2025 revenue of $6.2B (down 3% YoY) and adjusted EBITDA of $1.9B (flat YoY), maintaining margins despite gross margin compression. 2026 guidance projects flat revenue ...

Organon reported a disappointing Q4, with revenue down 5% YoY and significant weakness in women's health. Shares are heavily oversold, but I maintain a Hold rating due to strategic uncertainty and ...